158 related articles for article (PubMed ID: 37946141)
21. [Significance of glypican-3 mRNA expression in hepatocellular carcinoma tissues and peripheral blood cells].
Li BD; Zhao QC; Zhu YT; Zhang FQ; Dou KF
Zhonghua Wai Ke Za Zhi; 2006 Apr; 44(7):458-62. PubMed ID: 16772080
[TBL] [Abstract][Full Text] [Related]
22. Development of a clinical chemiluminescent immunoassay for serum GPC3 and simultaneous measurements alone with AFP and CK19 in diagnosis of hepatocellular carcinoma.
Yu JP; Xu XG; Ma RJ; Qin SN; Wang CR; Wang XB; Li M; Li MS; Ma Q; Xu WW
J Clin Lab Anal; 2015 Mar; 29(2):85-93. PubMed ID: 24687454
[TBL] [Abstract][Full Text] [Related]
23. Predicting glypican-3 expression in hepatocellular carcinoma: A comprehensive analysis using combined contrast-enhanced ultrasound and clinical factors.
Li N; Dong T; Wang P; Li Q; Nie F
Clin Hemorheol Microcirc; 2023; 85(4):407-420. PubMed ID: 37638421
[TBL] [Abstract][Full Text] [Related]
24. GLS1 promotes proliferation in hepatocellular carcinoma cells via AKT/GSK3β/CyclinD1 pathway.
Xi J; Sun Y; Zhang M; Fa Z; Wan Y; Min Z; Xu H; Xu C; Tang J
Exp Cell Res; 2019 Aug; 381(1):1-9. PubMed ID: 31054856
[TBL] [Abstract][Full Text] [Related]
25. Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway.
Li B; Cao Y; Meng G; Qian L; Xu T; Yan C; Luo O; Wang S; Wei J; Ding Y; Yu D
EBioMedicine; 2019 Jan; 39():239-254. PubMed ID: 30555042
[TBL] [Abstract][Full Text] [Related]
26. Expression profile and prognostic value of glypican-3 in post-operative South Korean hepatocellular carcinoma patients.
Jeon Y; Kim H; Jang ES; Hong S; Kim JW; Yoon YS; Cho JY; Han HS; Jeong SH
APMIS; 2016 Mar; 124(3):208-15. PubMed ID: 26764243
[TBL] [Abstract][Full Text] [Related]
27. Significance of Glypican-3 (GPC3) Expression in Hepatocellular Cancer Diagnosis.
Sun B; Huang Z; Wang B; Yu Y; Lin S; Luo L; Wang Y; Huang Z
Med Sci Monit; 2017 Feb; 23():850-855. PubMed ID: 28207681
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of glypican-3 in patients with HBV-associated hepatocellular carcinoma after liver transplantation.
Cui X; Li Z; Gao PJ; Gao J; Zhu JY
Hepatobiliary Pancreat Dis Int; 2015 Apr; 14(2):157-63. PubMed ID: 25865688
[TBL] [Abstract][Full Text] [Related]
29. Long noncoding RNA glypican 3 (GPC3) antisense transcript 1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3.
Zhu XT; Yuan JH; Zhu TT; Li YY; Cheng XY
FEBS J; 2016 Oct; 283(20):3739-3754. PubMed ID: 27573079
[TBL] [Abstract][Full Text] [Related]
30. Long noncoding RNA MyD88 functions as a promising diagnostic biomarker in hepatocellular carcinoma.
Wang Z; Gao P; Sun W; Rehman AU; Jiang J; Xu S; Xue C; Zhu C; Qin X
Front Endocrinol (Lausanne); 2023; 14():938102. PubMed ID: 36793272
[TBL] [Abstract][Full Text] [Related]
31. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.
Feng H; Li B; Li Z; Wei Q; Ren L
BMC Cancer; 2021 Apr; 21(1):401. PubMed ID: 33849479
[TBL] [Abstract][Full Text] [Related]
32. Nomograms to predict the long-time prognosis in patients with alpha-fetoprotein negative hepatocellular carcinoma following radical resection.
Huang J; Liu FC; Li L; Zhou WP; Jiang BG; Pan ZY
Cancer Med; 2020 Apr; 9(8):2791-2802. PubMed ID: 32096346
[TBL] [Abstract][Full Text] [Related]
33. The Value of GPC3 and GP73 in Clinical Diagnosis of Hepatocellular Carcinoma.
Jing JS; Ye W; Jiang YK; Ma J; Zhu MQ; Ma JM; Zhou H; Yu LQ; Yang YF; Wang SC
Clin Lab; 2017 Nov; 63(11):1903-1909. PubMed ID: 29226636
[TBL] [Abstract][Full Text] [Related]
34. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.
Capurro M; Wanless IR; Sherman M; Deboer G; Shi W; Miyoshi E; Filmus J
Gastroenterology; 2003 Jul; 125(1):89-97. PubMed ID: 12851874
[TBL] [Abstract][Full Text] [Related]
35. Golgi protein 73, not Glypican-3, may be a tumor marker complementary to α-Fetoprotein for hepatocellular carcinoma diagnosis.
Wang Y; Yang H; Xu H; Lu X; Sang X; Zhong S; Huang J; Mao Y
J Gastroenterol Hepatol; 2014 Mar; 29(3):597-602. PubMed ID: 24236824
[TBL] [Abstract][Full Text] [Related]
36. MRI-Based Radiomics Signature: A Potential Biomarker for Identifying Glypican 3-Positive Hepatocellular Carcinoma.
Gu D; Xie Y; Wei J; Li W; Ye Z; Zhu Z; Tian J; Li X
J Magn Reson Imaging; 2020 Dec; 52(6):1679-1687. PubMed ID: 32491239
[TBL] [Abstract][Full Text] [Related]
37. Quantitative image features of gadoxetic acid-enhanced MRI for predicting glypican-3 expression of small hepatocellular carcinoma ≤3 cm.
Dong SY; Sun W; Xu B; Wang WT; Yang YT; Chen XS; Zeng MS; Rao SX
Clin Radiol; 2023 Oct; 78(10):e764-e772. PubMed ID: 37500336
[TBL] [Abstract][Full Text] [Related]
38. [Expression and clinicopathologic significance of GPC3 and other antibodies in well-differentiated hepatocellular carcinoma].
DU JL; Wei LX; Wang YL
Zhonghua Bing Li Xue Za Zhi; 2011 Jan; 40(1):11-6. PubMed ID: 21429352
[TBL] [Abstract][Full Text] [Related]
39. Correlation between HBV protein preS2 and tumor markers of hepatocellular carcinoma.
Luan F; Liu B; Zhang J; Cheng S; Zhang B; Wang Y
Pathol Res Pract; 2017 Sep; 213(9):1037-1042. PubMed ID: 28869105
[TBL] [Abstract][Full Text] [Related]
40. Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma.
Lee HJ; Yeon JE; Suh SJ; Lee SJ; Yoon EL; Kang K; Yoo YJ; Kim JH; Seo YS; Yim HJ; Byun KS
Gut Liver; 2014 Mar; 8(2):177-85. PubMed ID: 24672660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
